Commentary

Article

State of the Science Summit - Hematology: Chaired by Mikkael Sekeres, MD

In Partnership With:

State of the Science Summit - Hematology: Chaired by Mikkael Sekeres, MD

State of the Science Summit - Hematology: Chaired by Mikkael Sekeres, MD

Speakers

  • Mikkael Sekeres, MD | Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System
  • Terrence Bradley, MD | Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System
  • Namrata Chandhok, MD | Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System
  • Alvaro Alencar, MD | Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System
  • Juan Alderuccio, MD | Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System
  • Gerald Soff, MD | Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System
  • Diana Brynes, MD | Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System

Topics

  • The Role of JAK Inhibitors in Myelofibrosis (MF)
  • How do you manage patients with myelodysplastic syndromes (MDS)?
  • Year in Review: 2023 Updates in CLL
  • Year in Review: 2023 Updates in DLBCL
  • Venous thromboembolism (VTE)
  • Hematology & Pregnancy
  • Live Q&A
Related Videos
C. Ola Landgren, MD, PhD
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Related Content
Mark R. Litzow, MD
July 24th 2024

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

Mikkael A. Sekeres, MD, professor, medicine, chief, Division of Hematology, Leukemia Section, University of Miami Sylvester Comprehensive Cancer Center
July 1st 2024

FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia

FDA
July 23rd 2024

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

D. Ross Camidge, MD, PhD; Jashodeep Datta, MD, assistant professor, surgery, co-leader, Gastrointestinal Site Disease Group, University of Miami Sylvester Comprehensive Cancer Center, associate director, Translational Research, the Sylvester Pancreatic Cancer Research Institute
May 27th 2024

Camidge and Datta Detail the Career of an “Opportunistic Nomad”

C. Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center
July 19th 2024

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD, professor, medicine, chief, Division of Myeloma, Department of Medicine, director, Sylvester Myeloma Institute, co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
July 18th 2024

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment